Coaching-forward GLP-1 program — strong on behavioral support, less on pricing transparency
Found is a coaching-forward weight-loss telehealth program that combines GLP-1 prescribing with behavioral coaching, habit tracking, and a structured curriculum. For patients who feel they need the support scaffolding around medication rather than just the prescription, Found's program is reasonable. The clinical bench supports the full FDA-approved formulary plus older agents and a compounded pathway.
The $99/month program fee is competitive in the program-fee tier, and the coaching content is more developed than at most competitors who treat behavioral support as an afterthought. Found is mature enough to have well-documented patient support and reliable shipping.
Found's pricing is layered — program fee plus medication, with the medication tier varying by the specific drug and dose. Total monthly cost can be higher than published headline pricing suggests. The clinical depth is competent but not specialist-led, and for patients with complex metabolic histories, Form Health or NexLife are stronger picks. Found's compounded pathway exists but is not the cheapest in market.
Found is a reasonable choice for patients who want behavioral coaching tightly integrated with GLP-1 prescribing. NexLife wins on cash-pay flat-rate; Form wins on clinical depth.
Found pricing ranges from $99/mo + medication. Starting price is $99/month. Pricing details and any titration upcharges are described above in the pricing section.
Found is an established telehealth program. Coaching-forward option. Good for non-GLP-1 candidates too. Always verify a provider's pharmacy partnerships, prescribing physician credentials, and state availability before signing up.
Most direct-to-consumer compounded GLP-1 programs do not accept insurance for the medication itself. If insurance coverage matters to you, see our insurance pathway providers (Mochi Health, Ro, Form Health) and our insurance hub.
Found prescribes: Wegovy, Zepbound, Saxenda, Contrave, Compounded options.
Found is available in All 50 states.
Eligibility is determined by an intake questionnaire and clinical review. Generally, FDA-approved weight-loss criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing is at the discretion of the prescribing clinician.
Editorial note. By GLP Agonists Editorial · Last updated May 2026. This review is editorially independent. See our methodology and editorial disclosure. Not medical advice — always consult a licensed clinician.